<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Caspian Journal of Internal Medicine</title>
<title_fa></title_fa>
<short_title>Caspian J Intern Med</short_title>
<subject>Medical Sciences</subject>
<web_url>http://caspjim.com</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2008-6164</journal_id_issn>
<journal_id_issn_online>2008-6172</journal_id_issn_online>
<journal_id_pii>8</journal_id_pii>
<journal_id_doi>10.22088/cjim</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>14</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>13</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1396</year>
	<month>10</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2018</year>
	<month>1</month>
	<day>1</day>
</pubdate>
<volume>9</volume>
<number>2</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Is 99m Tc-methylene diphosphonate bone scintigraphy a sensitive method for detecting bone lesions in multiple myeloma?</title>
	<subject_fa>Hematology</subject_fa>
	<subject>Hematology</subject>
	<content_type_fa>Original Article</content_type_fa>
	<content_type>Original Article</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;span style=&quot;font-size:14px;&quot;&gt;&lt;span style=&quot;font-family:times new roman;&quot;&gt;&lt;span style=&quot;color:#0000FF;&quot;&gt;&lt;strong&gt;&lt;em&gt;Background:&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt; Bone lesion in multiple myeloma (MM) is most commonly presented as a lytic lesion in this disease. Determination of extent of bone lesions in MM is necessary to follow-up the patients. Whole body bone scan with 99m, Tc-methylene diphosphonate (MDP) has a lower sensitivity than other modalities.&lt;br&gt;
&lt;span style=&quot;color:#0000FF;&quot;&gt;&lt;strong&gt;&lt;em&gt;Methods&lt;/em&gt;&lt;/strong&gt;&lt;em&gt;:&lt;/em&gt;&lt;/span&gt; From the patients with MM admitted to Ayatollah Rouhani Hospital of Babol-Iran from 2009 to 2015, who had undergone whole body bone scan during diagnostic process, were entered into the study. Findings of bone scan were compared with MRI.&lt;br&gt;
&lt;span style=&quot;color:#0000FF;&quot;&gt;&lt;strong&gt;&lt;em&gt;Results:&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt; Of the 19 patients, sixteen (84.2%) of them had positive finding in bone scan, fifteen (78.9%) had MRI of the spine. While of the thirteen patients who had positive finding in MRI, seven (53.8%) had more positive finding in thorcolumbosacral MRI than in bone scan.&lt;br&gt;
&lt;span style=&quot;color:#0000FF;&quot;&gt;&lt;strong&gt;&lt;em&gt;Conclusions:&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt; 99m-Tc MDP bone scan is a sensitive but insufficient method for detecting bone lesions in MM.&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;p align=&quot;right&quot; dir=&quot;RTL&quot;&gt;&lt;/p&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Tc-99m methylene diphosphonate, bone lesion, multiple myeloma</keyword>
	<start_page>140</start_page>
	<end_page>143</end_page>
	<web_url>http://caspjim.com/browse.php?a_code=A-10-117-1&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Mohsen</first_name>
	<middle_name></middle_name>
	<last_name>Vakili-sadeghi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>mvakili89@gmail.com</email>
	<code>100319475328460011949</code>
	<orcid>100319475328460011949</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Babol university of medical sciences2.	Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Sadegh</first_name>
	<middle_name></middle_name>
	<last_name>Sedaghat</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>sadeghsedaghat@yahoo.com</email>
	<code>100319475328460011950</code>
	<orcid>100319475328460011950</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
